Neurovascular Guidewires Market Estimated to Grow at a CAGR of 3.9% During the Forecast Period 2018 To 2028

Neurovascular Guidewires Market - Key Research Findings

1. Global neurovascular guidewires market size in 2018 – Nearly US$ 262 Mn
2. Neurovascular guidewires market is projected to record a CAGR of 3.9% during the forecast period (2018–2028).
3. According to the Centers for Disease Control and Prevention (CDC),
   
   • The prevalence of ischemic strokes (2016) was approximately 87% in the US alone.
4. North America and Europe will remain the largest regional markets for neurovascular guidewires.
   
   • The rising number of minimally invasive surgeries & neurovascular neuroradiology procedures, advancements in technology, the adoption of new equipment, and the rising prevalence of neurovascular diseases are among the key factors that are likely to assist growth of the neurovascular guidewires market.
5. East Asia holds a high growth potential for the neurovascular guidewires market, as the demand for new treatment options is rapidly increasing, driven by the rising burden of aneurysm and neurovascular diseases in the region.
6. Straight tip guidewires are likely to witness maximum growth rate in the neurovascular guidewires market through 2028.
   
   • The nature of micro-sensors and fiber optics, ease of operability, and high accuracy in neurovascular intervention procedures have resulted ain extensive usage of laser straight tip guidewires.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3121

 

Top 4 Factors Shaping the Neurovascular Guidewires Market

• Rising number of minimally invasive surgeries and neurovascular neuroradiology procedures

According to the Centers for Disease Control and Prevention, about 87% of all strokes are ischemic strokes and around 10% of these strokes result in death within a period of one month. According to the American Stroke Association, the annual stroke prevalence in the US reach around 800,000 – resulting in approximately 130,000 deaths, every year.

The World Health Organization claims that one death by stroke occurs every 10 seconds around the world. The rising prevalence of neurovascular diseases, especially strokes & cerebral infarctions, and the requirement of surgical procedures, are expected to drive the neurovascular guidewire market.

More than 50 million surgical procedures were performed in the US in 2016 and every year, the number of surgical procedures is growing. Moreover, the preference for minimally invasive surgeries is increasing. Neurovascular guidewires are used in various minimally invasive surgeries because of their specifications such as their thinness and flexibility, which enables them to be easily inserted into the body to guide larger equipment or instruments such as feeding tubes, catheters, and others. Improvements in surgical procedures and the increasing demand for minimally invasive surgeries is boosting the usage of neurovascular guidewires during minimally invasive interventional procedures.

• Rising prevalence of neurovascular diseases is likely to boost the neurovascular guidewires market

At present, around 87% of the people worldwide are suffering from stroke, according to the Centers for Disease Control and Prevention. The incidence of ischemic stroke is predicted to increase, especially in the lower to middle-income or underdeveloped countries, according to the World Bank Group. Micro-sensors and fiber optic guidewires improve the results of several surgical procedures, thus broadening the utilization of guidewires from neurovascular diseases to coronary & urological diseases.

• Positive outcomes of clinical trials are expected to contribute to the expansion of neurovascular guidewires market

Clinical trials have demonstrated the benefits of guidewires such as lubricious coating, sterility, and biocompatibility, efficacy in the treatment procedure of aneurysm, cerebral infarction, and ischemic stroke, which is another factor estimated to the boost the neurovascular guidewires market.

The ongoing studies of new technologies to improve the quality of treatment with the help of neuro-intervention procedures, such as a gold coil at the tip for radio capacity and a distal tip that is specially engineered for neuro-intervention procedures, are expected to support the growth of neurovascular guidewires market.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-3121

• Increasing number of neurovascular neuroradiology procedures and technological advancements

The increasing number of neurovascular neuroradiology procedures is boosting the demand for access products, which is driving the usage of guidewires. Aneurysm and AVM procedures require 1.7 to 1.8 cm guidewire per procedure, and new technology innovations for the treatment of ischaemic stroke, such as stents, are driving the adoption of neurovascular guidewires. Neurovascular guidewires improve the distal navigation and trackability features of the guidewires that are used in various complex neurovascular intervention procedures.

Significant advancements have been witnessed in guidewire technology, which have resulted in the initial success rates, as well as decreased the difficulties pertaining to the usage of guidewires. Developments in guidewire technology as well as in their framework have resulted in enhanced the efficacy and safety of movable wire systems.

Neurovascular Guidewires Market Structure Analysis

• Tier 1 companies are focusing on strategic mergers, acquisitions, and collaborative agreements in an effort to strengthen sales and distribution networks.
• Asahi Intecc Co., Ltd recently signed an agreement with another industry giant, Medtronic plc, over distribution of neurovascular guidewires. The company also announced direct sales of percutaneous transluminal coronary angioplasty (PTCA) guidewires in the US.
• Stryker Corporation recently announced the acquisition of K2M Group Holdings Incorporation, over a minimally invasive solutions range.

Dental Hygiene Devices Market Size, Worth, Share, Outlook, Trends, Insights, Forecast to 2028 by Future Market Insights Report

Prominently operated by Colgate-Palmolive Company, Glaxo Smith Kline plc, Johnson & Johnson, P&G, Unilever plc, and Dentsply Sirona, the dental hygiene devices landscape is currently witnessing dominance of toothbrush sales. In recent years, the dramatic growth of the E-commerce sector is translating into elevating online sales of dental hygiene devices, which is posing strong competition facing the retail pharmacy segment.

Toothbrush Records Highest Sale, Online Retail Firms up

A recent market research study by Future Market Insights provides exclusive insights on the current and prospective performance of global dental hygiene devices market, in terms of sales volume as well as revenue.

“The report categorizes dental hygiene devices landscape into the toothbrush, scalers, polishing devices, and others on the basis of product type. Toothbrush has been the top-selling product in global dental hygiene devices landscape, attributed to widespread availability, extensive selection range, broad price range, and frequent innovation,” explains a senior research analyst at FMI.

Currently, toothbrush sales account for almost 60% of the total market revenue, whereas the report indicates that dental scalers and dental polishing devices are gradually gaining ground. The study projects over 5% year over year revenue growth for the latter two in 2019 and ahead.

Retail pharmacies will remain the largest revenue generating channel of distribution in dental hygiene devices market. Whereas, online pharmacies are slated to present promising investment opportunities to dental hygiene devices manufacturers. The report projects that revenue generated through online retail would cross the US$ 1 billion mark in the next 3-4 years.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8177 

Key Dynamics Prompt at Rising Oral Care Concerns

The global dental hygiene devices market is low-value high-volume landscape, which remains the key factor that dampens investment. While baby boomers have been referred to as the primary consumers of dental hygiene devices, a growing percentage of juvenile and millennial people afflicted with one or more oral health problems points to the widening prospects of dental hygiene devices in coming years.

Increasing dental disease prevalence, coupled with the increasingly sophisticating infrastructure of dental care across developing regions, is predominantly responsible for improving the scope of dental hygiene devices penetration. Dental caries, periodontal conditions, and oral cancer mark some of the most significant concerns related to oral healthcare, among the population.

“OTC (over-the-counter) nature of a majority of dental hygiene devices remains one of the key factors positively influencing their widespread availability and sales,” says the FMI analyst.

Adding further to it on the potential market growth barriers, the analyst says, “As dental disorders are often non-life threatening, a notable portion of the patient population tends to initially prefer alternative treatments over dental hygiene devices. Price pressure and poor RoI are identified to be longstanding challenges for manufacturers of dental hygiene devices to initiate large scale investment projects”.

Asian Economies Create an Attractive Investment Pocket

The report sheds light on all the aspects related to worldwide demand for dental hygiene devices and offers insights on the growth prospects projected for global dental hygiene devices market through the next few years. The report forecasts steady yet moderate yearly revenue growth of 4.7% in 2019, and around 1/3^rd of the total market value is poised to be accounted for by the Asia Pacific. North America and Western Europe are likely to hold a collective share of more than a third of the global market value.

APAC and Latin America are poised to remain highly lucrative regional markets for manufacturers of dental hygiene devices owing to consistently increasing demand for dental treatments in these regions.

Although the widening patient pool is driving the steady demand for dental hygiene devices, a sizeable population based in developing countries is still undiagnosed and untreated. FMI research points to the presence of several untapped opportunities in a massive untreated population and thereby highlights high attractiveness of emerging regional markets for dental hygiene devices manufacturers.

Besides frequent product innovations, key players in the global dental hygiene devices market maintain their strategic focus on the enhancement of distribution channel by strengthening existing marketing efforts across Asian markets, particularly in India, Singapore, and Malaysia.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-8177

Toothpaste Innovations Account for a Trending Wave

The report suggests that strategic collaborations, new product launches, and geographical expansion remain the highlights of developmental strategies adopted by key companies operating in dental hygiene devices landscape. Electric/battery-operated toothbrush innovations continue to shape new launch strategies of a majority of companies, whereas most of the market leaders are focusing on introducing novel toothpaste ranges specific to various oral care demands.

• GSK recently unveiled a range of Aquafresh Advance specifically for 9-12 years olds' demographic, targeting enamel protection and cavity prevention. The company's Consumer Healthcare arm also launched a new Sensodyne Rapid Relief range in the US.
• P&G also released a new toothpaste range recently, specifically for improved gum health.
• Dabur India Ltd. launched a modern variant of their flagship toothpaste range i.e. ayurvedic specialist toothpaste in gel format.

Surgical Generators Market Growth, Analysis Report With B. Braun Melsungen, Olympus Corporation | Forecast - 2028

Leading Manufacturers in the Surgical Generators Market Contribute 45% Revenue Share

The surgical generators market is dominated by the key manufacturers that are focused on providing regulatory compliant and technologically advanced medical devices in order to increase the acceptance of surgical generators. Portable devices with advanced technology and short technical time combined with superior user interface are being provided by the major companies operating in the global surgical generators market. The major manufacturers in surgical generator market upholding large revenue share are Ethicon (J&J), Bovie Medical Corporation, Olympus Corporation, CONMED Corporation, Medtronic, Soring, CooperSurgical, and KLS Martin. The latest offering by manufacturers includes Argon Plasma Coagulation Generators. Compatibility and electrical output transducer are seamlessly integrated to the surgical generators devices. In further addition to this, there is a major focus on improving safety features in the global surgical generators market to reduce the probabilities of burns and injury and consequently improve patient safety. Manufacturers are constantly introducing new and improved products in the global surgical generators market with emphasis on research and development in the electrosurgical radiofrequency generator. Furthermore, constant research and development is projected to generate substantial market growth during the study period.

Growing Demand for Advanced Energy Devices in Operation Theaters and Emergency Rooms

Integrated operating rooms have evolved and revolutionized the way surgeries are performed in the recent times. The new technologies have transformed the electrosurgery and associated devices. Modern-day integrated operating theaters are built with advanced hi-tech technologies that intended to maximize the productivity and efficiency. The advancement in surgical generators have modernized the concept of minimal invasive surgeries. The ultra-precision in performing the cut and coagulation by the utilization of Argon Plasma Coagulation Generators have minimum side effects. New advanced ultrasonic generators and electrosurgical radiofrequency (RF) generators are capable of handling variations in the input requirement of ablation devices and cautery, additionally the increased compatibility of surgical generators with the ablation devices have made the surgical generator a choice of instrument in operation theaters, which is expected to nurture the growth of the surgical generator market. In developed countries such as the U.S. and Germany the preferred location for performing surgeries is hospitals, rather than clinics, to reduce the vulnerability of getting nonstandard healthcare infrastructure, which increases the adoption of surgical generators in hospitals and ambulatory surgical centers.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-663 

Specialized Distribution Channels for Surgical Generators

The manufacturers of surgical generators are offering their devices through retail channels. Also, they are offering their approved devices through specialized distribution channels to clinics. The vertical integration strategy has given them a competitive edge over standard ablation device manufacturers. Hospitals that purchase surgical generators devices receive financial aid from government authorities in developed countries. For instance, Medtronics, in 2016 launched Valleylab FT10 energy platform, and Valleylab FT10 receives financial aid from government to facilitate the purchase.

Availability of Safety-oriented Surgical Generators

The conventional surgical generators are being rapidly replaced with advanced devices, on the account of increasing focus on safety associated with the electrosurgical devices. Medical device manufacturers operating in the electrosurgical radiofrequency generators market are focusing on providing enhanced safety features to the end users to minimize chances of burns and increase patient safety. MEGADYNE MEGA POWER Electrosurgical Generator manufactured by Ethicon US LLC. (Johnson & Johnson), is equipped with an additional electrode Protection System (EPS) which protects the patient’s skin from damage. During the electrosurgical procedure, when the fluctuations in the electrical current or anomaly in output from surgical generator are detected at the anode tip, EPS system turns off the electrosurgical generator which reduces the risk of burns.

Competitive Landscape

This section of the report features profiles of the major key players operating in the surgical generators market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. Examples of some of the key players featured in this report include Boston Scientific Corporation, Bovie Medical Corporation, B. Braun Melsungen, Olympus Corporation, CONMED Corporation, ERBE Elektromedizin GmbH, Bowa, Medtronic, Soring, CooperSurgical, Ethicon and KLS Martin.

The key manufacturers of surgical generators are focusing on technological advancement to capture large share in the market. The companies offering low capacity surgical generators devices are concentrating on promoting dynamic pricing strategies. These companies are offering their products with additional operating training. Conventional distribution channels, such as hospitals, clinics, and online channels, are expected to be the key target of the key manufacturers.

Request to View Methodology @ https://www.futuremarketinsights.com/askus/rep-gb-663

Definition

The workflow of electrosurgical radiofrequency (RF) generator follows the conversion principle where electromagnetic energy is first transformed into kinetic energy due to resistance to current flow then to thermal energy. The preferred effect in the tissue is resulted based on number of electromagnetic properties as well as elements relative as contact point and tissue exposure time additionally the dimensions and profile of the surface of the anode pole near to or in contact with the target tissue.

Hypoparathyroidism Treatment Market Trends and Predictions Explore By Emerging Players — Sun Pharmaceutical Industries Ltd., AbbVie Inc.

50% of the Revenue Contribution by the Leading Players

The hypoparathyroidism treatment market is largely dominated by the major players, who are competing on the basis of market penetration and distribution. The consolidated nature of the hypoparathyroidism treatment market increases the profitability. Factors such as poor efficacy and efficiency of the treatment are hampering the adoption of hypoparathyroidism treatment. However, the growing awareness regarding hypoparathyroidism treatmentand number of thyroid surgeries are expected to create growth opportunities for the manufacturers operating in the ****** hypoparathyroidism treatment market. Shire-NPS Pharmaceuticals, Inc., EnteraBio Ltd., and Teva Pharmaceutical Industries Ltd. hold more than 50% revenue share in the ****** hypoparathyroidism treatment market. The growth of the ****** hypoparathyroidism treatment market is primarily driven by growing prevalence of hypoparathyroidism and increasing number of thoracic surgeries and incidence of cancer. Thedevelopment of healthcare infrastructure across the globe coupled with governmental support for hypoparathyroidism treatment is expected to drive the growth of the hypoparathyroidism treatment market. The companies operating in the market are involved in developing new experimental hypoparathyroidism treatment drugs.

Increasing Number of Thoracic Surgeries and Incidence of Cancer

The growing screening rates, increasing number of thoracic surgeries and incidence of cancer are expected to be the prime factors driving the growth of the hypoparathyroidism treatment market. Thyroid or neck surgery is associated with hypoparathyroidism, owing to damage to the parathyroid glands. The number of thyroidectomies in the U.S. reflects 39% increase from 2007 to 2015. This indicates transient post-surgical hypoparathyroidism, which can become permanent in about 25% of cases. The growing incidence of head & neck and thyroid cancers is the other factor expected to drive the growth of the market.

Increasing investments in the research and development coupled with the development of biologics is expected to generate momentum and growth opportunities for the hypoparathyroidism treatment market.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7857

New Drug Development and Government Support to Root Out Hypoparathyroidism

New drug development is expected to create enormous growth opportunity for the hypoparathyroidism treatment market. Any new curative hypoparathyroidism treatment drug is expected to witness fast adoption with minimal resources due to lack of competition in the hypoparathyroidism treatment market. Symptomatic treatment is the chief goal of hypoparathyroidism treatment as there is no treatment for hypoparathyroidism.

The support to hypoparathyroidism treatment products and initiatives by the governments of different countries such as financial incentives and orphan status are the other factors expected to boost the growth of the hypoparathyroidism treatment market. The demographic drivers of the hypoparathyroidism treatment market include growing geriatric population and healthcare expenditure across the globe.

Growing Purchasing Power and Attractive Reimbursements

In the North America hypoparathyroidism treatment market, the U.S. is expected to be the dominant country as it is a large economy and with high purchasing power. Besides, favorable reimbursements for hypoparathyroidism treatment is also expected to support the growth of the hypoparathyroidism market. Likewise, large presence of major players such as Shire-NPS Pharmaceuticals, Inc., and EnteraBio Ltd., among others, is also expected to drive the growth of the hypoparathyroidism treatment market in the U.S. The healthcare expenditure in the U.S. was almost 16% of its GDP in 2017, which reflects better pricing and market attractiveness for the hypoparathyroidism treatment market.

Request to View Methodology @ https://www.futuremarketinsights.com/askus/rep-gb-7857

Orphan Status and Incentives

The U.S. FDA’s orphan status to drugs and biologics that affect less than 200,000 people in the U.S. confer various incentives such as tax credits for qualified clinical trials and market exclusivity upon regulatory approval. In the hypoparathyroidism treatment market, Natpara is an approved drug with a black box warning notified by the U.S. FDA in January 2015 – enjoying an exclusivity period till 2022.

Competitive Landscape

This section of the report features the profiles of the key players in the hypoparathyroidism treatment market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. The key players operating in the hypoparathyroidism treatment market include Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., and EnteraBio Ltd.